ArticleFrontiers in immunology2018
A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- MHC Attention: Identifying HLA-E presented cancer antigens through deep learning and high-throughput screening.bioRxiv : the preprint server for biology · 2026Article
- Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026Review
- Signals in the Cells: Multimodal and Contextualized Machine Learning Foundations for Therapeutics.bioRxiv : the preprint server for biology · 2024Article
- Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression.Journal for immunotherapy of cancer · 2024Article
- Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy.Cancer cell · 2022Article
- Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.Science translational medicine · 2022Article
- Revisiting the Principles of Designing a Vaccine.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Tapasin-mediated editing of the MHC I immunopeptidome is epitope specific and dependent on peptide off-rate, abundance, and level of tapasin expression.Frontiers in immunology · 2022Article
- CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.Frontiers in immunology · 2022Article
- The self-peptide repertoire plays a critical role in transplant tolerance induction.The Journal of clinical investigation · 2021Article
- Should Nano-Particles be Weighed or Counted? Technical Considerations to In Vitro Testing Originated from Corpuscular Nature of Nano-Particles.Archivum immunologiae et therapiae experimentalis · 2021Review
- The immunopeptidomes of two transmissible cancers and their host have a common, dominant peptide motif.Immunology · 2021Article
- Characterization of the Class I MHC Peptidome Resulting From DNCB Exposure of HaCaT Cells.Toxicological sciences : an official journal of the Society of Toxicology · 2021Article
- Genome-Wide Regulation of Acupuncture and Moxibustion on Ulcerative Colitis Rats.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model.Oncoimmunology · 2020Article
- HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8Cancer immunology research · 2019Article
- Mapping the stochastic sequence of individual ligand-receptor binding events to cellular activation: T cells act on the rare events.Science signaling · 2019Article
- AnFrontiers in immunology · 2019Article
- Specific MHC-I Peptides Are Induced Using PROTACs.Frontiers in immunology · 2018Article
- CD8OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Major histocompatibility complex-I (MHC-I) molecules play a central role in the immune response to viruses and cancers. They present peptides on the surface of affected cells, for recognition by cytotoxic T cells. Determining which peptides are presented, and in what proportion, has profound implications for developing effective, medical treatments. However, our ability to predict peptide presentation levels is currently limited. Existing prediction algorithms focus primarily on the binding affinity of peptides to MHC-I, and do not predict the relative abundance of individual peptides on the surface of antigen-presenting cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.